Article

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas

2025-07-15

Abstract excerpt

Astrocytomas and oligodendrogliomas are slow-growing and treatment-sensitive IDH-mutant gliomas diagnosed at ages 30-50. Local tumor regrowth and treatment resistance is inevitable resulting in 3-10 year astrocytoma and up to >20 years oligodendroglioma survival. We sought to identify genetic changes associated with tumor evolution in response to therapy through multi-timepoint whole-genome/whole-exome sequencing...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cfe9b774-3ca0-5af3-a9f1-1a53ce53bb84
DOI: 10.1101/2025.07.11.664189

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomasDOI 10.1101/2025.07.11.664189Read

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Semantic proximity Read

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant gliomaSemantic proximity Read

Genetic evolution and cellular interactions within the tumour microenvironment determine glioblastoma progressionSemantic proximity Read

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.Semantic proximity Read

Genomic alterations of oligodendrogliomas at distant recurrence.Semantic proximity Read

The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.Semantic proximity Read

The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimenSemantic proximity Read

Mutational landscape and clonal architecture in grade II and III gliomas.Semantic proximity Read

Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor PairsSemantic proximity Read

Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesSemantic proximity Read

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.Semantic proximity Read